PARP9

Across TCGA pan-cancer cohorts, PARP9 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of PARP9’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where PARP9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PARP9 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

BLCA, HNSC, and KIRC are the cancer types where PARP9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PARP9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	+1.232	<.001	11	view →
HNSC	All	III,IV	+1.030	<.001	11	view →
KIRC	Female	All	+0.861	<.001	11	view →
BRCA	All	III,IV	+1.045	<.001	8	view →
STAD	All	II,III,IV	+1.034	<.001	8	view →
THCA	Male	All	+0.627	<.001	8	view →
ESCA	All	All	+1.656	.002	4	view →
READ	All	III,IV	+0.725	.040	2	view →
PRAD	All	All	+0.468	<.001	2	view →
KIRP	All	All	+0.351	.009	2	view →
LUAD	Female	All	+0.238	.012	2	view →
LUSC	Male	III,IV	−1.017	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

PARP9–BLCA

Open the BLCA breakdown →